NYSE · Biotechnology

Ambrx Biopharma Inc. (AMAM) Stock

$28.00 +0.07% NYSE: AMAM Healthcare

Ambrx Biopharma Inc. operates as a clinical-stage biotechnology company focused on the discovery and development of precisely engineered biologic medicines.

Valuation

MetricValue
Price$28.00
Market Cap$1.77B
P/E Ratio-13.86
P/B Ratio9.17
P/S Ratio239.41
EPS (TTM)$-2.02
52-Week High$28.15
52-Week Low$6.55
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-50.68%
ROA-53.07%
ROCE-43.80%
Gross Margin100.00%
Operating Margin-771.16%
Net Margin-1114.29%
Debt/Equity0.10
Current Ratio5.44

Annual Financials (USD)

Metric2019202020212022
Revenue$10.0M$14.0M$7.0M$7.0M
Operating Profit$-22.0M$-13.0M$-64.0M$-57.0M
Net Profit$-22.0M$-18.0M$-68.0M$-78.0M
EPS$-0.59$-0.47$-3.34$-2.02
Op Margin-217.9%-95.9%-864.2%-771.2%

Balance Sheet (USD)

Metric2019202020212022
Total Assets$62.0M$134.0M$229.0M$147.0M
Total Liabilities$26.0M$272.0M$39.0M$29.0M
Cash$15.0M$90.0M$170.0M$56.0M
Borrowings$5.0M$3.0M$13.0M$12.0M

Latest News

Argentine Football Association says US did not detain its president AFP · Jul 23, 2026 Dow Jones Futures Rise; Google, Tesla Fall On Earnings, Capex, But AI Stocks Climb Investor's Business Daily · Jul 23, 2026 HD Hyundai Heavy Industries Reaches Major Milestone in ITER Nuclear Fusion Project PR Newswire · Jul 23, 2026 PBCO Financial Corporation Reports Q2 2026 Results Business Wire · Jul 23, 2026 US announces civilian nuclear deal with Saudi Arabia AFP · Jul 23, 2026

Cash Flow (USD)

Metric2019202020212022
Operating Cash Flow$-3.0M$-21.0M$-45.0M$-69.0M
Investing Cash Flow$0$-1.0M$-6.0M$-48.0M
Financing Cash Flow$0$96.0M$127.0M$1.0M
Net Cash Flow$-3.0M$75.0M$80.0M$-114.0M
Free Cash Flow$-3.0M$-21.0M$-48.0M$-70.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.19
EV / EBITDA-27.36
FCF Yield-3.93%
Quick Ratio5.21
Interest Coverage-58.97
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BIESFBiotest AG $32.00 +0.00% 48.06 $1.60B 0.16%
BLUBELLUS Health Inc. $14.75 +0.03% -22.34 $1.87B 0.00%
DICEDICE Therapeutics, Inc. $47.55 +0.06% -22.97 $2.27B 0.00%
EQRXEQRx, Inc. $2.34 -2.09% 5.44 $1.14B 0.00%
FUSNFusion Pharmaceuticals Inc. $21.55 +0.14% -14.86 $1.83B 0.00%

About Ambrx Biopharma Inc.

Ambrx Biopharma Inc. operates as a clinical-stage biotechnology company focused on the discovery and development of precisely engineered biologic medicines. The firm utilizes its unique expanded genetic code technology platform to create these advanced therapies. Leading its pipeline is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is currently undergoing evaluation in several clinical investigations. These include pivotal Phase 2/3 trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer, alongside studies for other solid tumors. Additionally, Ambrx is progressing two earlier-stage drug candidates: ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for prostate cancer and other solid tumor indications; and ARX305, an anti-CD70 ADC, currently in investigational new drug (IND)-enabling studies for potential applications in renal cell carcinoma and other cancers. The company's portfolio also encompasses multiple immuno-oncology programs. Among these are ARX822, a fab-small molecule bispecific therapeutic in preclinical development for various cancers, and ARX102, an immuno-oncology IL-2 pathway agonist intended to stimulate the patient's immune system by targeting beta and gamma receptors on cytotoxic T cells. Founded in 2003 and headquartered in La Jolla, California, Ambrx Biopharma Inc. has established significant collaborations with various pharmaceutical partners, including Bristol Myers Squibb Company, AbbVie Inc., BeiGene, Sino Biopharmaceutical Co., Ltd., NovoCodex, and Elanco Animal Health.

Ambrx Biopharma Inc. is headquartered in US.

Ambrx Biopharma Inc. (AMAM) stock trades at $28.00 with a market capitalization of $1.77B. The stock is valued at a price-to-earnings (P/E) ratio of -13.86, price-to-book of 9.17, price-to-sales of 239.41. Over the past 52 weeks the stock has ranged between $6.55 and $28.15, and currently trades at its 52-week high.

On profitability, Ambrx Biopharma Inc. generates a return on equity (ROE) of -50.68%, return on capital employed of -43.80%, an operating margin of -771.16%, a net profit margin of -1114.29%.

Official website: ambrx.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNYSE High ROE StocksAll stock screens
Run Stock Screener Investing Guides